BioCentury | Dec 31, 2020
Distillery Therapeutics

Protease inhibitor SERPINB9 as a melanoma, breast cancer target

DISEASE CATEGORY: Cancer INDICATION: Melanoma; breast cancer Inhibiting SERPINB9, a serine protease inhibitor, could treat melanoma and breast cancer. In a melanoma mouse model, tumor-specific SERPINB9 knockout reduced tumor size and the number of melanoma...
BioCentury | Oct 3, 2019

SERPINB1 and CXCR6 inhibition for multiple sclerosis

DISEASE CATEGORY: Autoimmune disease INDICATION: Multiple sclerosis (MS) Blocking the leukocyte esterase inhibitor SERPINB1 or the chemokine receptor CXCR6 could help treat MS. In the experimental autoimmune encephalomyelitis (EAE) mouse model of MS, systemic knockout...
BioCentury | Aug 3, 2019
Emerging Company Profile

Bringing CAR T to India

A company formed this year in Bangalore by Kiran Mazumdar-Shaw, Kush Parmar and Siddhartha Mukherjee plans to bring a CAR T therapy to cancer patients in India for about $50,000 per treatment. That cost, which...
BioCentury | Nov 3, 2018
Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
BioCentury | Sep 13, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: August 2018

New Therapeutic Targets and Biomarkers: August 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in August 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Aug 21, 2018
Preclinical News

Two algorithms could better predict response to checkpoint inhibitors

While checkpoint inhibitors have revolutionized immunotherapy, many patients don't respond to the inhibitors, and there are currently no accurate diagnostics to predict who will respond. Two papers in Nature Medicine put forth algorithms that use...
BioCentury | Aug 9, 2018
Distillery Techniques

Drug platforms

...combination of chemokine CC motif ligand 5 (RANTES; CCL5), thrombospondin-1 (TSP-1; THBS1) and plasminogen activator inhibitor 1 (SERPINE1; PAI1...
...5 (RANTES) (CCL5) Insulin-like growth factor (IGF) binding protein 2 (IGFBP2) Macrophage migration inhibitory factor (MIF) Plasminogen activator inhibitor 1 (SERPINE1) (PAI1) Thrombospondin-1...
BioCentury | Jul 18, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Peptides A fibrin matrix loaded with synthetic laminin peptides that bind growth factors could be used for wound healing and tissue regeneration applications. The peptides are 24- and 19-mer synthetic analogs of human laminin...
BioCentury | Dec 8, 2017
Company News

Daiichi returns TS23 rights to Translational Sciences

Daiichi Sankyo Co. Ltd. (Tokyo:4568) returned to Translational Sciences Inc. (Memphis, Tenn.) exclusive, worldwide rights for TS23. The companies partnered in 2015 to develop and commercialize the blood clot-dissolving antibody (see BioCentury, Oct. 19, 2015...
BioCentury | Nov 1, 2017
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other...
Items per page:
1 - 10 of 97